From Morphology to Molecularly Integrated Diagnosis: Contemporary Neuropathology Practice in Neuro-Oncology
Abstract
The practice of neuropathology in neuro-oncology has undergone a fundamental transformation. For much of the twentieth century, central nervous system (CNS) tumours were classified predominantly according to their microscopic resemblance to presumed cells of origin, architectural patterns, and histological features of malignancy. Although histopathology remains indispensable, the identification of recurrent genetic and epigenetic alterations has demonstrated that morphologically similar tumours may represent biologically distinct diseases, while tumours with variable histology may share a common molecular identity. The fifth edition of the World Health Organization (WHO) Classification of Tumours of the Central Nervous System, published in 2021, consolidated this transition by making molecular alterations essential diagnostic criteria for numerous tumour types. The contemporary neuropathology report is therefore an integrated diagnosis incorporating morphology, immunophenotype, molecular findings and CNS WHO grade. The present review discusses the continuing role of conventional histology and immunohistochemistry (IHC) and examines the applications, advantages and limitations of targeted platforms such as fluorescence in situ hybridisation (FISH), Sanger sequencing and reverse transcription polymerase chain reaction (RT-PCR). It further outlines the expanding role of next-generation sequencing (NGS) and genome-wide deoxyribonucleic acid (DNA) methylation profiling in CNS tumour classification. A rational, tiered approach combining morphology with appropriately selected molecular platforms offers the most practical route towards accurate, reproducible and clinically relevant diagnosis, particularly in settings where access to comprehensive genomic testing remains limited.